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Introduction
The subventricular zone (SVZ) lining the lateral ven-
tricles is a source of stem cells that generate olfactory
bulb interneurons throughout adulthood (1–3). EGF
and its family of receptors are involved in proliferation
of the adult neural stem/progenitor cells (4–9). Intra-
ventricular infusion of EGF expands the SVZ cell pop-
ulation and promotes cell migration into adjacent
brain parenchyma, including striatum (7, 8). Whether
these migrating SVZ cells survive long term and give
birth to differentiated neuronal populations after brain
injury remains unknown.
Ischemic stroke is a particularly interesting model of
brain injury because it causes selective death of neuronal
subpopulations in the striatum (10–13). Spiny projec-
tion neurons containing dopamine and adenosine 3′,5′-
monophosphate–regulated phosphoprotein of 32KD
(DARPP-32+) and aspiny parvalbumin-containing (PV+)
interneurons die in the ischemic lesion, whereas many
aspiny somatostatin-containing (SS+) or cholinergic
interneurons survive (10–14). These aspiny interneurons
are known to provide the bulk of the inhibitory control
of spiny projection neurons (15), and the disruption of
the striatal neuronal circuits after stroke is considered to
cause functional deficits. It is tempting to speculate that
a role for adult neurogenesis would be to compensate for
the loss of dead neurons and favor differentiation into
specific neurons, i.e., in the case of ischemic striatum, in
spiny projection and PV+ neurons rather than SS+ neu-
rons. Indeed, it was reported recently that a small num-
ber of endogenous precursor cells differentiate into
DARPP-32+ projection neurons within the ischemic
striatum (16). The number of neurons replaced at 6
weeks after ischemia remains small, however (0.2% of the
number of neurons lost after ischemia). Clearly, these
results demonstrate that endogenous neural stem cells
produce very incomplete replacement of dying neurons
in cases of severe injury (17). In the present study, we
asked two fundamental questions: Could EGF increase
neurogenesis in the injured brain, and if so, would EGF
promote the replacement of both interneurons and pro-
jection neurons?
Here we show that in the ischemic striatum, admin-
istration of EGF in an albumin-containing vehicle for
1 week increases neuronal replacement 100-fold
compared with vehicle. Intraventricular infusion of
EGF with albumin increased the population of SVZ
cells that colabeled with BrdU and doublecortin,
indicating that EGF increases the number of neu-
ronal precursor cells that eventually migrate into the
ischemic lesion and differentiate into neurons. Sixty-
five percent of these newborn striatal neurons
matured into PV+ interneurons. Most importantly,
more than 20% of PV+ neurons lost after ischemia
were replaced in the group treated with EGF. Our
results suggest that neuronal replacement can be
manipulated by exogenous growth factors such as
EGF to achieve significant restoration of neuronal
subpopulations lost after ischemic injury.
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Methods
Animals and surgery. Animal care and experimental pro-
tocols complied with The Principles of Laboratory Ani-
mal Care (NIH’s Guide for the Care and Use of Labora-
tory Animals). Ten-week-old male 129S6/SvEvTac mice
(Taconic Farms, Germantown, New York, USA) were
anesthetized with 3% isoflurane and maintained on
1–1.5% isoflurane in 70% N2O and 30% O2 using a Fluo-
tec 3 vaporizer (Colonial Medical Supply, Amherst, New
Hampshire, USA). Regional cerebral blood flow was
measured by laser-Doppler flowmetry (PF2B; Perimed,
Stockholm, USA). The left MCA was occluded with an 
8-0 nylon monofilament (Ethicon Inc., Somerville, New
Jersey, USA) coated with a mixture of silicone resin (Xan-
topren; Bayer Dental Nippon KK, Osaka, Japan) and a
hardener (Elastomer Activator; Bayer Dental Nippon
KK), as described (18). Twenty minutes later, the fila-
ment was withdrawn, and reperfusion was confirmed by
laser-Doppler flowmetry. Neuronal loss was restricted to
the ipsilateral striatum (Figure 1a). In a control group,
mice were subjected to surgery, but the nylon filament
was not introduced into the carotid artery.
EGF (human recombinant EGF; Sigma-Aldrich, St.
Louis, Missouri, USA) was diluted in PBS containing
BSA (Sigma-Aldrich) and unilaterally infused into the
lateral ventricle using an osmotic pump (1007D; Alza
Corp., Mountain View, California, USA) attached to a
cannulae (brain infusion kit II; Alza Corp.) implanted at
1.4 mm lateral and 0.6 mm caudal to bregma to a depth
of 1.8 mm from the dura. Albumin was added as a carri-
er upon recommendation of the EGF manufacturer and
added at a concentration of 1 mg/ml, consistent with
recent reports studying neurogenesis (7, 8, 19, 20). EGF
was infused 2 days after ischemia for 7 days at a flow rate
of 0.5 µl/h with an initial intrapump concentration of 33
or 3.3 µg/ml (400 or 40 ng/d). Therefore, albumin was in
3- and 30-fold molar excess compared with EGF (400
ng/d) and EGF (40 ng/d), respectively. In another set of
experiments, EGF (400 ng/d) was infused 21 days after
ischemia for 7 days. In that group, cell proliferation was
assessed on day 28 and doublecortin (DCX) and glial fib-
rillary acidic protein (GFAP) immunohistochemistry
was performed 5 weeks after the end of the infusion (8
weeks after ischemia). The vehicle solution was sterile
PBS containing 1 mg/ml BSA.
BrdU injections. Animals received intraperitoneal
injections of BrdU (Sigma-Aldrich; 50 mg/kg; dis-
solved in sterile PBS and 0.007 N HCl and filtered at
0.22 µm). Twice daily injections were given on days 7
and 8 after brain injury.
Immunohistochemistry. For histological evaluation, the
animals were perfused transcardially with 4% para-
formaldehyde in PBS under deep anesthesia. Immuno-
histochemistry was performed on free-floating 40-µm
coronal sections, as reported previously (8, 18). The sec-
tions were stained using the following antibodies and
dilutions: anti-BrdU (1:400; Becton Dickinson Immuno-
cytometry Systems, San Jose, California, USA), 1:400;
Accurate Chemical & Scientific Corp., Westbury, New
York, USA), anti–neuronal nuclear antigen (NeuN)
(1:400; Chemicon International, Temecula, California,
USA), anti-nestin (1:500; PharMingen, San Diego, Cali-
fornia, USA), anti–EGF receptor (1:200; Santa Cruz
Biotechnology Inc., Santa Cruz, California, USA), anti-
DCX (1:400; Santa Cruz Biotechnology Inc.), anti-Tuj1
(1:500; Covance Research Products Inc., Berkeley, Cali-
fornia, USA), anti-GFAP (1:500; Sigma-Aldrich), anti-PV
(1:500; Chemicon International), anti–DARPP-32 (1:100,
Santa Cruz Biotechnology Inc.), anti-SS (1:200; Santa
Cruz Biotechnology Inc.), biotinylated anti-mouse IgG
(1:200; Vector Laboratories, Burlingame, California,
USA), avidin-biotin-peroxidase complex (1:200; Vectas-
tain Elite; Vector Laboratories), and secondary antibod-
ies conjugated with cy2, cy5, or rhodamine red-X (1:400;
Jackson ImmunoResearch Laboratories Inc., West Grove,
Pennsylvania, USA). Anti-NeuN antibodies labeled with
cy5 were prepared according to the manufacturer’s pro-
cedure (FluroLink mAb cy5 labeling kit; Amersham
International, Amersham, United Kingdom).
Quantification. All analyses were accomplished with
stereologic counting methods. A systematic random sam-
pling of every 12th in a series of 40-µm coronal sections
was prepared from each animal and processed for
immunohistochemistry. The striatum evaluated in this
study was focused on the region from bregma 0.3–1.3
mm, since infarct area in the striatum ipsilateral to the
insult was constant within the focused region in our pilot
study. Counting of BrdU+ or PV+ cells was performed in
the striatum in three sections per animal using a ×40
objective lens. The striatum was divided into two regions
by a centerline as medial and lateral part. The areas of the
striatum on each section were measured on the adjacent
sections stained with cresyl violet using an MCID Imag-
ing Research image analysis system (Imaging Research
Inc., St. Catherines, Ontario, Canada). The striatal vol-
ume (STV) after ischemia was measured in the striatum
in a hemisphere within bregma 0.3–1.3 mm by the image
analysis using the Cavalieri technique (21). In this study,
there was not significant difference in the STV between
vehicle- and EGF-treated groups, although the STV
decreased during the period between 9 days and 13 weeks
following ischemia (data not shown). The number of
BrdU+ or PV+ cells within the STV then was calculated by
multiplying volume density (cells per millimeter cubed)
of the labeled cells by the STV.
Counting of BrdU+ cells coexpressing DCX, NeuN, or
PV was performed using a Nikon TE 400 microscope
with a laser confocal scanning system MRC 1024 (Bio-
Rad Laboratories Ltd., Wattford, United Kingdom). For
each animal, the number of double-labeled cells was
counted in the ipsilateral striatum using three sections
as described above. Cells were determined double labeled
when BrdU and DCX or NeuN immunoreactivity over-
lapped in at least five levels through a section (z-step, 1
µm). Neuronal replacement index (NRI) was obtained by
determining the ratio between the number of newly born
neurons present in the striatum (BrdU+PV+ cells) and the
estimate of the number of dead PV+ neurons. The latter
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was determined by estimating the number of PV+ cells in
the contralateral striatum and subtracting it from the
number of PV+ cells in the ischemic striatum (excluding
the newly born PV+ cells). The final equation is expressed
as a percentage according to the following formula: 
NRI = 100 × (number of BrdU+PV+ cells in ipsilateral stria-
tum) / (total number of PV+ cells in contralateral stria-
tum) – [(total number of PV+ cells in ipsilateral striatum)
– (number of BrdU+PV+ cells in ipsilateral striatum)] (%).
Statistical analyses. All values are expressed as mean
plus or minus SD. Mann-Whitney test or unpaired
Student t tests in StatView 5.0 for Macintosh were used
for statistical analysis throughout the study. Dose
responsiveness of EGF was evaluated using regression
analysis. P values less than 0.05 were considered statis-
tically significant. At least five to six animals were used
for each experiment unless otherwise specified.
Results
EGF-enhanced proliferation after ischemia. To optimize the
timing of EGF infusion, we examined EGF receptor
expression in neural progenitor cells in SVZ following
20 min of middle cerebral artery occlusion. Neural pro-
genitor cells were defined as SVZ cells expressing nestin,
a marker for multipotent neural stem/progenitor cells
during development (2, 7). After focal cerebral ischemia,
EGF receptor expression in the nestin+ SVZ cells
increased as early as 1 day (Figure 1, b and c), reached
maximal expression at 3 days (Figure 1d), decreased at
9 days (not shown), and returned to basal levels at 21
days (Figure 1e). We also examined endogenous EGF
expression in striatum at 1, 3, and 7 days following
ischemic injury. Despite increased expression of EGF
receptor in nestin+ cells, we were unable to detect sig-
nificant change in EGF in striatum homogenates using
Western blot analysis (data not shown), suggesting that
endogenous EGF levels remain low after injury (22–24).
Based on the immunohistochemical data, we started
intraventricular EGF administration on day 2, and com-
pared the effects of 7-day infusion of EGF or vehicle on
cell proliferation using BrdU incorporation into repli-
cating DNA (7, 8). A low dose of EGF (40 ng/day) was
sufficient to increase the number of BrdU+ cells 11-fold
in the medial striatum, but not in the lateral striatum,
compared with ischemia plus vehicle (Figure 1j). More-
over, increasing EGF dose to 400 ng/day further
increased the number of BrdU+ cells 1.5-fold in the medi-
al striatum (17-fold increase compared with ischemia
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Figure 1
EGF-enhanced proliferation after ischemia. (a) Ischemia reperfusion caused a marked loss of NeuN+ neurons (outlined area) confined to
the striatum (ST). SVZ, subventricular zone. Scale bar is 200 µm. (b–e) Without ischemia (b), few nestin+ cells (green) expressing EGF
receptors (red) surrounded the lateral ventricle (V). After ischemia, the intensity of EGF receptor immunoreactivity in nestin+ SVZ cells
(arrowheads) and the number of nestin+ cells expressing EGF receptor increased at 1 day (c), reached maximum at 3 days (d), and returned
to basal levels at 21 days (e). The dotted line delineates lateral ventricle. Scale bar is 20 µm (n = 3–4/time-point). (f–i) BrdU+ cells at 9 days
after sham or ischemia in an area corresponding to the box (a). After vehicle, the number of BrdU+ cells was higher after ischemia (g) than
sham (f) (quantification in j). Ischemia followed by EGF (I-E; 400 ng/day) increased BrdU+ cells and was greater when EGF infusion start-
ed 2 days (h) rather than 21 days (i) after ischemia. (f) Scale bar is 100 µm. Bregma, 0.8 mm. (j) Quantification. S-V, sham-operated; 
I-V, ischemic group with vehicle; I-E (2d), ischemic groups with EGF (400 ng/day) initiated at day 2; I-E (21d), day 21 after ischemia. The
effects of EGF (40 and 400 ng/day) initiated at day 2 were compared. +Significant difference between S-V and I-V; *between vehicle- and
EGF-treated ischemic groups; #between groups treated with EGF 2 days or 21 days; §between medial and lateral striatum within the same
group; n = 3–4/group, unpaired Student t test, P < 0.05.
plus vehicle), revealing a dose dependency following EGF
infusion (P < 0.05). Delayed administration of EGF (400
ng/day beginning at 21 days after ischemia) was less
effective, resulting in a 1.6-fold decrease in BrdU+ cells in
the medial striatum, compared with ischemia plus EGF
(400 ng/day initiated at 2 days after ischemia) (Figure 1,
i and j). These data suggest the importance of EGF-EGF
receptor signaling in cell proliferation early after stroke.
Migrating neuroblasts after EGF treatment. Five weeks after
ischemia, immature migrating neuroblasts labeled with
DCX (16, 25) were found throughout the medial stria-
tum when EGF (400 ng/day) infusion was initiated on
day 2, but not on day 21 (Figure 2, b and c). In EGF (400
ng/day initiated at day 2 after ischemia), DCX+ cells
were colabeled with a neuronal marker, Tuj1(2),
confirming their neuronal phenotype (Figure 2d).
The number of migrating neuroblasts was high in
the medial striatum adjacent to SVZ (Figure 2e).
Chains (and clusters) of DCX+ migrating neuro-
blasts appeared to link the SVZ and the striatal
lesion and were observed in the treated brain (Fig-
ure 2, f and g). Strikingly, EGF infusion also
increased GFAP+ cells exhibiting long processes fol-
lowing ischemia (Figure 2i). Moreover, GFAP+ cells
and their processes organized a network to link SVZ
and striatal lesion. This network was absent when
EGF infusion was delayed after ischemia (Figure 2j).
These observations suggest that a network of
GFAP+ cells could participate in the migration of
DCX+ cells toward the ischemic lesion and possibly
for trophic support or as a lattice for neuroblast
migration (26–28). Although our observations also
suggest that neuroblasts within the striatal lesion
originated from the SVZ as reported previously (16),
however, our data did not exclude the possibility
that neuroblasts also arose from resident precursors
or circulating stem cells (4, 5, 29). At 3 and 5 weeks
after ischemia, however, many DCX+ neuroblasts
were found outside the SVZ (Figure 2, b and l) with
a gradient of cells from SVZ to the lesion. These
findings are consistent with previous reports show-
ing that EGF infusion promotes division of precur-
sors (also referred to as SVZ type C cells expressing
EGF receptor) into neuroblasts (19) as well as
migration of SVZ cells into striatum (7). Taken
together, the data suggest that migrating neuro-
blasts within the ischemic striatum derived from
SVZ progenitors cells in response to EGF.
Neuronal differentiation in the ischemic striatum. At
13 weeks, the number of DCX+ plus BrdU cells
decreased in the lesion (Figure 2m) but not in the
intact area adjacent to the SVZ. Hence, DCX+ neu-
roblasts within the ischemic lesion either express
markers of mature neurons after losing their
DCX+ phenotype or die.
To elucidate whether immature neuroblasts dif-
ferentiate into mature neurons, we compared the
distribution and the number of BrdU+ cells
expressing DCX or NeuN (mature neuronal mark-
er) between 5 and 13 weeks after ischemia using two-
color confocal imaging with serial sections in the z
plane. BrdU+ striatal neurons expressing NeuN were
detected mainly at the boundary of the ischemic lesion
in medial striatum (Figure 3). In fact, there were 13-fold
more BrdU+NeuN+ cells in the medial striatum than in
the lateral striatum at 13 weeks (P < 0.01, data not
shown). A similar proportion was observed for DCX+
neuroblasts at 5 weeks (Figure 2). In addition, ischemia
and EGF administration augmented the absolute num-
ber of BrdU+NeuN+ cells with time (Table 1). The ratio
of BrdU+NeuN+ neurons to total BrdU+ cells increased
from 1.1% to 3.0% between 5 and 13 weeks (Table 1),
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Figure 2
Migrating neuroblasts after EGF treatment. (a) Using confocal
microscopy, 5 weeks after ischemia, very few DCX+ cells (red) were
observed in the striatal lesion (white solid line) after vehicle. DCX+ cells
dramatically increased by EGF infusion initiated on day 2 (b) but not on
day 21 (c) (n = 3–4 per group; for quantification see Table 1), revealing the
importance of EGF signaling for cell migration early after ischemia. (d)
Colocalization of DCX (red) and Tuj1 (green) confirmed their phenotype.
(e) DCX+ cells were predominantly within medial (M) relative to lateral (L)
striatum. (f and g) Chains or clusters of DCX+ (red) cells (arrowhead, mag-
nified in g) connecting SVZ and the striatal lesion were observed in medi-
al striatum (e). (h–j) GFAP+ glial cells (green) and DCX+ neuroblasts (red)
between SVZ (right end) and the damaged striatum (left side) were rare in
vehicle (h) or with EGF administration initiated at day 21 (j), compared
with EGF at day 2 post-ischemia (i). Note the orientation of GFAP+
processes in (i). (k–m) The spatial distribution and number of DCX+ (red)
cells changed with time after EGF. DCX+ cells were few at the end of the
infusion period (k) and progressively increased in the area devoid of NeuN+
cells (green) at 3 weeks (l) and 5 weeks (b). By 13 weeks, DCX+ were most-
ly outside the lesion (m), suggesting that DCX+ cells may have differenti-
ated into mature neurons. Scale bar is 50 µm except for (e), 100 µm. Breg-
ma, 0.8 mm. Dotted line, the border between SVZ and striatum.
whereas the number of DCX+ cells decreased (Figure 2,
b and m; Table 1). The distribution and the appearance
of mature neurons with time, taken together with a
decrease in the number of immature cells, suggested
that DCX+ neuroblasts differentiated into mature
NeuN+ neurons within the ischemic striatum. Some
BrdU+DCX+ cells may have died as well, as reflected by
the decrease in BrdU+DCX+ cells that became NeuN
positive from week 5 to 13 (Table 1).
The use of BrdU+ incorporation as a marker of cell
division and newly born neurons requires caution in
the injured brain because cells with DNA damage also
incorporate BrdU in the repair process (30). However,
the SVZ is remote from the ischemic lesion, and its cells
are unlikely to sustain DNA damage (31). Moreover,
two results suggest that BrdU incorporation reflected
division of progenitor cells in our experiments: (a) we
did not detect TUNEL staining in NeuN+ cells at 9 days
after ischemia (data not shown), and (b) there were no
BrdU+NeuN+ double-labeled cells in the striatum at 9
days after ischemia (peak of BrdU+ cell number). Taken
together, these results confirmed that BrdU+NeuN+
cells were not injured neurons that incorporated BrdU
as part of their DNA repair process, but were striatal
neurons differentiated from newly generated precursor
cells at 5 and 13 weeks after injury.
Phenotypes of the newly born neurons. We next deter-
mined whether newly born cells were differentiated
into specific neuronal phenotypes. Hence, we charac-
terized BrdU+NeuN+ neurons by immunohistochem-
istry using PV-, SS-, and DARPP-32–specific antibod-
ies. At 13 weeks after ischemia, numerous BrdU+NeuN+
striatal cells expressing PV were detected (Figure 4a) at
the boundary zone of the ischemic lesion (Figure 4e),
where new mature neurons were detected (Figure 3c).
In fact, there were 345 ± 69 BrdU+NeuN+PV+ cells from
a total of 525 ± 83 BrdU+NeuN+ cells (Figure 4f; Table
1) in the medial striatum, indicating that 65% of newly
born neurons differentiated into PV+ interneurons. The
remaining BrdU+NeuN+ cells did not express either SS
or DARPP-32 (Figure 4e), and their identity remains
unknown. Similar results were observed in the lateral
striatum although the overall number of BrdU-positive
neurons was much lower (data not shown). EGF
increases neuronal replacement of lost PV+ neurons
100-fold (21% ± 4% versus 0.2% ± 0.5% for vehicle
administration; Figure 4g), corresponding to a restora-
tion of the PV+ population to 60% of its number before
injury (Figure 4h). PV+ interneurons normally extend a
rich network of dendrites (32). Indeed, a rich network
of PV+ dendrites was visualized within injured striatum
(Figure 4a), demonstrating that these newly born neu-
rons also exhibit the morphological characteristics of
aspiny PV+ neurons. If the dendrites of these newly
born PV+ cells also contact 100 projection neurons, as
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Figure 3
Neuronal differentiation in the ischemic striatum. (a and c) Repre-
sentative confocal microscopic images of BrdU, DCX, and NeuN
colabeling showing that BrdU-labeled neurons (arrowheads) were
located in the boundary zone of the ischemic lesion at 5 (a) and 13
(c) weeks. A white solid line delineates the lesion area. Scale bar is 50
µm. (b and d) Confocal 3D analyses of BrdU+DCX+ cells at 5 weeks
(b) and BrdU+NeuN+ cells at 13 weeks (d) after ischemia. Recon-
structed orthogonal images are presented as viewed from the sides
in both the x-z (top) and y-z (right) planes. Arrowheads indicate dou-
ble-labeled cells. Scale bar is 10 µm. n = 5–6 per group (for quantifi-
cation, see Table 1).
Table 1
Numbers of newborn neurons in medial striatum at 5 and 13 weeks after ischemia
Group Weeks after ischemia (a) Total BrdU+ cells (b) BrdU+DCX+ cells % of (a)/(b) (c) BrdU+NeuN+ cells % of (c)/(a)
S-V 5 317 ± 56 Ud – Ud –
13 275 ± 64 Ud – Ud –
S-E 5 16,005 ± 2,178 120 ± 84 0.7 ± 0.5 Ud –
13 12,325 ± 1,893D 75 ± 50 0.6 ± 0.4 Ud –
I-V 5 1,182 ± 253 20 ± 21 1.6 ± 1.8 3 ± 3 0.3 ± 0.3
13 913 ± 227 Ud – 8 ± 13 0.8 ± 1.3
I-E 5 22,027 ± 4,378 815 ± 188A 3.7 ± 0.3 245 ± 134A 1.1±0.6
13 17,505 ± 2,943 110 ± 34B, C 0.7 ± 0.3C 525 ± 83B, C 3.0 ± 0.3
Infusion of EGF (400 ng/day) was initiated on day 2 after ischemia. Data correspond to number of cells per striatum and are expressed as mean ± S.D. 
(n = 5–6/group). Ud, undetected; S-V, sham-operated group with vehicle treatment; S-E, sham-operated group with EGF; I-V, ischemic group with vehicle; 
I-E, ischemic group with EGF. AP < 0.01 vs. I-V at 5 weeks; BP < 0.01 vs. I-V at 13 weeks; CP < 0.05 vs. I-E at 5 weeks; DP < 0.05 vs. S-E at 5 weeks, unpaired t test.
does the normal cell, the potential impact of these find-
ings to striatal function is impressive.
Injury was an important factor in the process of
neuronal replacement. In its absence, EGF alone
increased SVZ cell number, but did not promote mat-
uration of neuroblasts into neurons (Table 1; Figure
4). Ischemic injury itself stimulated neuronal replace-
ment, although the number of mature neurons
remained rare (Table 1; Figure 4). Therefore, EGF
receptor induction and glial activation in response to
ischemia, provided crucial substrates for EGF-medi-
ated neuronal replacement.
Discussion
Our results demonstrate that endogenous neuronal
replacement can be amplified after ischemic brain
injury and that EGF, only minimally expressed in
ischemic striatum, can enhance the neuronal recruit-
ment process. Early after ischemia, EGF receptor levels
increased in SVZ cells and in cell types such as neurons
and glia (33), and EGF receptor activation by acute
administration (within 30 min of ischemia) of ligands
reduced infarct volumes (34). Moreover, in
the adult as well as in the developing brain,
the expression of EGF receptors can stim-
ulate proliferation and migration of neu-
ral progenitor cells within SVZ (35–37). We
did not detect effects of EGF on infarct
volumes (data not shown), but observed
the effects of EGF infusion on neurogene-
sis, especially when EGF receptor expres-
sion was high in SVZ a few days after
ischemia but not at 21 days after ischemia
(Figure 1). These results suggest that EGF
treatment promotes cell proliferation and
migration through EGF receptor-mediat-
ed mechanisms.
Compared with albumin vehicle alone,
the number of newly generated neurob-
lasts and mature neurons was drastically
increased after EGF plus albumin admin-
istration (Table 1). Albumin was added to
the vehicle to stabilize EGF (as recom-
mended by Sigma-Aldrich) and to provide
consistent dosing especially in view of its
potential for degrading and sticking dur-
ing prolonged infusion (7 days) using a
pump reservoir (Alzet pump). Albumin
has important biological effects in
ischemia, and its role in neurogenesis has
not been well explored. Albumin reduces
ischemic injury and oxygen radical dam-
age during reperfusion when administered
acutely intravenously up to 24 hours after
ischemia (38–40). Albumin did not reduce
infarct size, however, when we infused the
albumin-containing vehicle intracere-
broventricularly 48 hours after ischemia
(data not shown). In retrospect, we wonder
whether the addition of albumin to the vehicle is nec-
essary because proliferation of SVZ cells or recruit-
ment of SVZ cells into the damaged striatum was
observed after infusion of an EGF receptor ligand
(heparin-binding EGF-like growth factor or TGF-α)
within striatum or ventricle in the absence of albumin
(41, 42). Furthermore, EGF in the absence of albumin
improved a learning response (passive avoidance) and
increased SVZ cell proliferation when administered
acutely to aged mice (43), although this response was
observed only when EGF was coadministered with
nerve growth factor (NGF). Finally, based on our own
data, any possible synergistic action of albumin on
neurogenesis would have to be EGF-specific because
coadministration of albumin plus FGF-2 failed to pro-
mote migration of newly born neuroblasts in the
ischemic striatum or differentiation into mature neu-
rons (data not shown). Nevertheless, our experiments
do not rule out the possibility that albumin enhanced
EGF’s action by a mechanism independent of protein
stabilization, and additional experiments directed at
studying albumin’s effects on EGF receptor binding
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Figure 4
Neuronal replacement in the ischemic striatum. (a) Confocal 3D reconstruction
revealed newborn PV+ neurons (arrowhead) triple-labeled with BrdU, NeuN, and
PV in the medial striatum of EGF-treated mice at 13 weeks after ischemia. (b–e)
The triple-labeling with BrdU, PV, and DARPP-32 revealed that newborn PV+ neu-
rons (e, arrowhead) were located in the boundary zone of the ischemic lesion.
White solid line delineates the lesion area. Scale bars are 20 µm. (f) Numbers of
BrdU+NeuN+PV+ cells in the medial striatum at 13 weeks after ischemia. Ud,
undetected in VAS-V and S-E groups. (g) NRI (see text) indicates ratio between
newborn neurons and the neurons lost after injury. (h) Progressive repopulation
of PV+ neurons in the ischemic striatum measured as a percentage of PV+ neu-
rons in ischemic striatum relative to the number in the nonischemic contralater-
al striatum. *Significant difference between ischemic group administered with
vehicle (I-V) or EGF (I-E) (P < 0.01); n = 5-6/group, unpaired Student t test.
and signal transduction (as well as the use of another
protein carrier) would be of interest.
Thirteen weeks after ischemia plus EGF administra-
tion, 65% of newly born neurons matured into PV+
neurons, one type of striatal GABAergic interneurons
(Figure 4) (15, 44). In the CNS, PV and other calcium-
binding proteins such as calbindin and calretinin play
a vital role in calcium homeostasis and are generally
thought of as calcium buffering rather than calcium
regulatory proteins (45). Despite this, a specific role of
parvalbumin in neuronal function is still unclear. In
the dt(sz) mutant hamster, however, a genetic model of
a type of paroxysmal dystonia, the number of PV+
GABAergic neurons was selectively reduced and
administration of GABA(A) receptor agonist musci-
mol improved the dystonic syndrome, supporting the
importance of striatal GABAergic PV+ interneurons in
the control of motor function (46). Similarly,
immunohistochemical analysis suggests that degen-
eration of PV+ interneurons are involved in the patho-
physiology of Huntington disease (47, 48). In stroke,
the rescue of PV+ striatal cells by BDNF partially
restores functional deficits (13). These results suggest
that regeneration of PV+ interneurons might help
functional recovery after injury and should be a part
of strategies to repair striatum, together with neuronal
replacement of other types of striatal interneurons and
projection neurons.
Unexpectedly, neuronal differentiation after EGF
administration was limited to PV+ neurons. Newly
born neurons did not mature into SS+-expressing
interneurons, or even DARPP-32+ projection neurons,
representing about 95% of the striatal neuronal popu-
lation (14). This result suggests that EGF favors the
expression of specific phenotypes during differentia-
tion of adult striatal progenitors. The absence of
DARPP-32+ neurons in the ischemic striatum after
EGF treatment, however, contrasts with EGF-mediat-
ed in vitro differentiation of progenitor cells into pro-
jection neurons (4, 5) and maturation of 42% of newly
born neurons into DARPP-32+ projection in the
ischemic rat striatum in the absence of EGF treatment
(16). The cause for these differences is still unclear. It
is possible that in the ischemic brain, EGF specifically
promoted maturation and differentiation of PV+ neu-
rons while possibly suppressing maturation and dif-
ferentiation of DARPP-32+ neurons. In the absence of
EGF treatment, our protocol for BrdU administration
limited the detection of BrdU+ cells after ischemia to
only about 1,000 cells (Table 1), and of those only
three to eight expressed a mature neuron phenotype
(NeuN+). Hence, it was not possible to identify the
phenotype of these infrequent BrdU-NeuN–positive
cells in the absence of EGF treatment. The absence of
DARPP-32+ neurons after EGF treatment could also be
due to species differences or severity of ischemia (2 h
versus 20 min). Additional studies will be necessary to
clarify this point and determine whether the newly
born PV+ cells are also GABAergic.
Ischemic injury provides important signals to
encourage cell migration and differentiation since
EGF infusion did not increase neurogenesis in the nor-
mal mouse striatum (Figure 4, Table 1). Similarly,
administration of EGF alone or with FGF-2 did not
increase neurogenesis in the injured spinal cord (49).
In contrast, EGF and FGF-2 infusion promotes neu-
ronal regeneration in the ischemic hippocampus, a
region where endogenous neurogenesis occurs in the
absence of injury (20). In the present study, we report
that ischemia enhances EGF-mediated neurogenesis
to replace neurons lost in the medial striatum, a region
usually devoid of neurogenesis. By 4 weeks after EGF
infusion alone, neuroblast migration was restricted to
an area adjacent to the SVZ. With ischemia, neurob-
lasts repopulated the lesion. In addition, EGF in the
absence of ischemia did not regulate neuronal differ-
entiation. The occasional DCX+ cell migrating toward
the intact striatum did not differentiate into mature
neurons after EGF, confirming other reports (8, 50). It
is unclear how ischemia promotes neuroblast migra-
tion and neuronal differentiation in EGF-treated ani-
mals. An early cue could be the expression of EGF
receptor on SVZ cells. Glia may also be important. We
found that EGF increased the number of activated glia
(GFAP+) between the SVZ and the ischemic lesion. In
addition, we found that GFAP+ cells tended to sur-
round neuroblasts migrating toward the ischemic
striatum at both 5 and 13 weeks after ischemia (Figure
2). Others reported that interactions between GFAP+
cells and neuronal precursors are necessary for neu-
roblast migration, differentiation, and/or survival in
the adult brain (26, 28, 51). Neurotransmitters and
growth factors such as stem cell factor, GABA, and glu-
tamate may be important for neuroblast migration
and neuronal differentiation (18, 22, 52, 53), as they
are during development (54–57). FGF-2 promotes neu-
ronal differentiation of EGF-responsive progenitor
cells in vitro (35, 58, 59), and FGF-2 levels increase in
striatum fivefold at 7 days after ischemia (data not
shown). We did not observe any effect of FGF-2 on
neuronal differentiation of newly born cells in the
ischemic striatum with doses that promoted cell pro-
liferation in SVZ (data not shown), however. These
results highlight that the proliferation of SVZ cells
alone is not sufficient to increase neuronal replace-
ment within the ischemic striatum. Further studies
examining the identity of specific microenvironmen-
tal cues that regulate EGF-mediated striatal neuroge-
nesis after ischemia could provide new opportunities
to promote repair in injured adult brain.
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